TAT-10: Targeted Alpha Therapy of Glioblastoma Multiforme: Clinical Experience with Bi213 and Ac225-Substance P
The Bi213 group contained 18 primary GBM and 7 secondary GBM subjects. Patients were treated with 1-7 doses of 2 GBq. In patients with primary GBM, the progression-free survival from the start of alpha therapy was 3.7 months. The median overall survival was 21.5 months from diagnosis and 9 months from recurrence. In patients with secondary GBM, the median progression-free survival was 13.6 months. Median overall survival was 46.8 months from diagnosis.
The Ac225 arm had 5 primary GBM patients. They were treated with 1-4 doses of 10 MBq in intervals of about 2 months. Median overall survival was 34 months from diagnosis and 12 months from recurrence.
The targeted alpha therapy was safe and well tolerated with both isotopes.
Presented By: Leszek Krolicki from the Department of Nuclear Medicine, Medical University of Warsaw, Poland
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.